Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 2Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Leukemia 8Leukemia, Myeloid, Chronic-Phase 6Blast Crisis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Sarcoma 4Melanoma 4Gastrointestinal Stromal Tumors 4Leukemia, Myeloid, Accelerated Phase 3Sarcoma, Synovial 2Oligodendroglioma 2Leukemia, Myeloid, Acute 2Glioma 2Colorectal Neoplasms 2Central Nervous System Neoplasms 2Brain Neoplasms 2Astrocytoma 2Uterine Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma, Endometrial Stromal 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma 1Refractory Desmoplastic Small Round Cell Tumors 1Prostatic Neoplasms 1Primary Myelofibrosis 1Piebaldism 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neurofibromatoses 1

Interventions

pembrolizumab 37Carboplatin 26Radiotherapy 23Cisplatin 19Paclitaxel 18Erlotinib Hydrochloride 18Docetaxel 15Gemcitabine 14Pemetrexed 13Etoposide 12osimertinib 11Nivolumab 11durvalumab 9atezolizumab 9Radiosurgery 8Magnetic Resonance Spectroscopy 8Cetuximab 7Specimen Handling 6Cyclophosphamide 6130-nm albumin-bound paclitaxel 6Taxes 5Immunoglobulin G 5Gefitinib 5Biopsy 5Bevacizumab 5fludarabine 4Radiation 4Ipilimumab 4Disulfides 4Albumin-Bound Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lung Neoplasms × Imatinib Mesylate × Clear all
NCT02127372 2014-09-15

Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571

Duke University

Phase 1/2 Terminated
43 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡